Publication: An anticonvulsive drug, valproic acid (valproate), has effects on the biosynthesis of fatty acids and polyketides in microorganisms
Issued Date
2020-12-01
Resource Type
ISSN
20452322
Other identifier(s)
2-s2.0-85086108402
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Scientific Reports. Vol.10, No.1 (2020)
Suggested Citation
Prapassorn Poolchanuan, Panida Unagul, Sanit Thongnest, Suthep Wiyakrutta, Nattaya Ngamrojanavanich, Chulabhorn Mahidol, Somsak Ruchirawat, Prasat Kittakoop An anticonvulsive drug, valproic acid (valproate), has effects on the biosynthesis of fatty acids and polyketides in microorganisms. Scientific Reports. Vol.10, No.1 (2020). doi:10.1038/s41598-020-66251-y Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/58411
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
An anticonvulsive drug, valproic acid (valproate), has effects on the biosynthesis of fatty acids and polyketides in microorganisms
Abstract
© 2020, The Author(s). Valproic acid or valproate (VPA) is an anticonvulsive drug used for treatments of epilepsy, bipolar disorder, and migraine headaches. VPA is also an epigenetic modulator, inhibiting histone deacetylase, and it has been subjected to clinical study for cancer treatment. During the investigation of VPA on a metabolite profile in a fungus, we found that VPA has significant effects on the production of some fatty acids. Further exploration of VPA on fatty acid profiles of microorganisms, fungi, yeast, and bacteria, as well as representative gut microbiome, revealed that VPA could enhance or reduce the production of some fatty acids. VPA was found to induce the production of trans-9-elaidic acid, a fatty acid that was previously reported to have cellular effects in human macrophages. VPA could also inhibit the production of some polyketides produced by a model fungus. The present work suggests that the induction or inhibition of fatty acid biosynthesis by VPA (100 µM) in gut microbiome could give effects to patients treated with VPA because high doses of VPA oral administration (up to 600 mg to 900 mg) are used by patients; the concentration of VPA in the human gut may reach a concentration of 100 µM, which may give effects to gut microorganisms.